Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results.
马萨诸塞州剑桥，2024年5月8日（GLOBE NEWSWIRE）——专注于识别和开发罕见病和耐多药（MDR）细菌感染的新疗法的多资产临床阶段生物制药公司Spero Therapeutics, Inc.（纳斯达克股票代码：SPRO）今天宣布，将在5月15日星期三公布其2024年第一季度财务业绩，并提供其业务和产品线的最新情况市场关闭。该公司不打算举办电话会议，并预计将在公布2024年第二季度业绩时恢复季度财报电话会议。
About Spero Therapeutics
关于斯佩罗疗法
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.
Spero Therapeutics总部位于马萨诸塞州剑桥，是一家多资产、处于临床阶段的生物制药公司，专注于识别和开发针对罕见疾病和耐多药（MDR）细菌感染的新疗法。
- Spero Therapeutics is developing its wholly owned lead product candidate, SPR720 as a novel oral, first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), currently advancing in a Phase 2A proof of concept study. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections.
- Spero Therapeutics正在开发其全资主要候选产品 SPR720，这是一种治疗非结核分枝杆菌肺病（NTM-PD）的新型口服一线疗法，目前正在进行2A期概念验证研究。NTM-PD 是一种罕见的肺部疾病，由非结核分枝杆菌感染引起。
- Tebipenem HBr is an investigational oral drug advancing in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories.
- Tebipenem HBr是一种正在研究的口服药物，正在进行3期注册试验，用于治疗包括肾盂肾炎在内的复杂尿路感染（CUTi）。Spero授予葛兰素史克独家许可，允许其在除某些亚洲地区以外的所有地区将替比培南HBr商业化。
- SPR206 is an innovative, investigational IV-administered direct-acting next generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies. An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
- SPR206 是一种创新的、正在研究的静脉注射直接作用的下一代多粘菌素，在临床前研究中已显示出对耐多药革兰氏阴性病原体的抗生素活性，包括耐碳青霉烯类肠杆菌、鲍曼不动杆菌和铜绿假单胞菌。一项研究性新药 (IND) 申请已获得 FDA 批准，旨在将 SPR206 推进为针对医院获得性或呼吸机相关细菌性肺炎参与者的二期临床试验。
For more information, visit .
欲了解更多信息，请访问 。
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
arr@lifesciadvisors.com
(617) 775-5956
投资者关系联系人：
阿什莉·罗宾逊
LifeSCI Advisors, LLC董事总经理
arr@lifesciadvisors.com
(617) 775-5956
Media Inquiries: media@sperotherapeutics.com
媒体查询：media@sperotherapeutics.com